Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AML
April 14th 2023Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.
Read More